Pirfenidone

Revision as of 16:51, 15 January 2015 by Gloria Picoy (talk | contribs) (Created page with "{{DrugProjectFormSinglePage |authorTag={{GP}} |genericName=Pirfenidone |aOrAn=a |drugClass=respiratory agent |indicationType=treatment |indication=idiopathic pulmonary fibrosi...")
(diff) ← Older revision | Latest revision (diff) | Newer revision → (diff)
Jump to navigation Jump to search

Pirfenidone
Adult Indications & Dosage
Pediatric Indications & Dosage
Contraindications
Warnings & Precautions
Adverse Reactions
Drug Interactions
Use in Specific Populations
Administration & Monitoring
Overdosage
Pharmacology
Clinical Studies
How Supplied
Images
Patient Counseling Information
Precautions with Alcohol
Brand Names
Look-Alike Names

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Gloria Picoy [2]

Disclaimer

WikiDoc MAKES NO GUARANTEE OF VALIDITY. WikiDoc is not a professional health care provider, nor is it a suitable replacement for a licensed healthcare provider. WikiDoc is intended to be an educational tool, not a tool for any form of healthcare delivery. The educational content on WikiDoc drug pages is based upon the FDA package insert, National Library of Medicine content and practice guidelines / consensus statements. WikiDoc does not promote the administration of any medication or device that is not consistent with its labeling. Please read our full disclaimer here.

Overview

Pirfenidone is a respiratory agent that is FDA approved for the treatment of idiopathic pulmonary fibrosis (IPF). Common adverse reactions include nausea, rash, abdominal pain, upper respiratory tract infection, diarrhea, fatigue, headache, dyspepsia, dizziness, vomiting, anorexia, gastro-esophageal reflux disease, sinusitis, insomnia, weight decreased, and arthralgia.

Adult Indications and Dosage

FDA-Labeled Indications and Dosage (Adult)

Pirfenidone is indicated for the treatment of idiopathic pulmonary fibrosis (IPF).

  • Dosage:
  • 267 mg (1 capsule) ORALLY 3 times daily for 7 days
  • Then 534 mg (2 capsules) ORALLY 3 times daily on days 8 through 14
  • Then 801 mg (3 capsules) ORALLY 3 times daily thereafter
  • All doses should be taken with food
  • Doses greater than 2403 mg/day not recommended

Off-Label Use and Dosage (Adult)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pirfenidone in adult patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pirfenidone in adult patients.

Pediatric Indications and Dosage

FDA-Labeled Indications and Dosage (Pediatric)

There is limited information regarding Pirfenidone FDA-Labeled Indications and Dosage (Pediatric) in the drug label.

Off-Label Use and Dosage (Pediatric)

Guideline-Supported Use

There is limited information regarding Off-Label Guideline-Supported Use of Pirfenidone in pediatric patients.

Non–Guideline-Supported Use

There is limited information regarding Off-Label Non–Guideline-Supported Use of Pirfenidone in pediatric patients.

Contraindications

None

Warnings

There is limited information regarding Pirfenidone Warnings' in the drug label.

Adverse Reactions

Clinical Trials Experience

There is limited information regarding Pirfenidone Clinical Trials Experience in the drug label.

Postmarketing Experience

There is limited information regarding Pirfenidone Postmarketing Experience in the drug label.

Drug Interactions

There is limited information regarding Pirfenidone Drug Interactions in the drug label.

Use in Specific Populations

Pregnancy

Pregnancy Category (FDA): There is no FDA guidance on usage of Pirfenidone in women who are pregnant.
Pregnancy Category (AUS): There is no Australian Drug Evaluation Committee (ADEC) guidance on usage of Pirfenidone in women who are pregnant.

Labor and Delivery

There is no FDA guidance on use of Pirfenidone during labor and delivery.

Nursing Mothers

There is no FDA guidance on the use of Pirfenidone in women who are nursing.

Pediatric Use

There is no FDA guidance on the use of Pirfenidone in pediatric settings.

Geriatic Use

There is no FDA guidance on the use of Pirfenidone in geriatric settings.

Gender

There is no FDA guidance on the use of Pirfenidone with respect to specific gender populations.

Race

There is no FDA guidance on the use of Pirfenidone with respect to specific racial populations.

Renal Impairment

There is no FDA guidance on the use of Pirfenidone in patients with renal impairment.

Hepatic Impairment

There is no FDA guidance on the use of Pirfenidone in patients with hepatic impairment.

Females of Reproductive Potential and Males

There is no FDA guidance on the use of Pirfenidone in women of reproductive potentials and males.

Immunocompromised Patients

There is no FDA guidance one the use of Pirfenidone in patients who are immunocompromised.

Administration and Monitoring

Administration

There is limited information regarding Pirfenidone Administration in the drug label.

Monitoring

There is limited information regarding Pirfenidone Monitoring in the drug label.

IV Compatibility

There is limited information regarding the compatibility of Pirfenidone and IV administrations.

Overdosage

There is limited information regarding Pirfenidone overdosage. If you suspect drug poisoning or overdose, please contact the National Poison Help hotline (1-800-222-1222) immediately.

Pharmacology

There is limited information regarding Pirfenidone Pharmacology in the drug label.

Mechanism of Action

There is limited information regarding Pirfenidone Mechanism of Action in the drug label.

Structure

There is limited information regarding Pirfenidone Structure in the drug label.

Pharmacodynamics

There is limited information regarding Pirfenidone Pharmacodynamics in the drug label.

Pharmacokinetics

There is limited information regarding Pirfenidone Pharmacokinetics in the drug label.

Nonclinical Toxicology

There is limited information regarding Pirfenidone Nonclinical Toxicology in the drug label.

Clinical Studies

There is limited information regarding Pirfenidone Clinical Studies in the drug label.

How Supplied

There is limited information regarding Pirfenidone How Supplied in the drug label.

Storage

There is limited information regarding Pirfenidone Storage in the drug label.

Images

Drug Images

{{#ask: Page Name::Pirfenidone |?Pill Name |?Drug Name |?Pill Ingred |?Pill Imprint |?Pill Dosage |?Pill Color |?Pill Shape |?Pill Size (mm) |?Pill Scoring |?NDC |?Drug Author |format=template |template=DrugPageImages |mainlabel=- |sort=Pill Name }}

Package and Label Display Panel

{{#ask: Label Page::Pirfenidone |?Label Name |format=template |template=DrugLabelImages |mainlabel=- |sort=Label Page }}

Patient Counseling Information

There is limited information regarding Pirfenidone Patient Counseling Information in the drug label.

Precautions with Alcohol

Alcohol-Pirfenidone interaction has not been established. Talk to your doctor about the effects of taking alcohol with this medication.

Brand Names

There is limited information regarding Pirfenidone Brand Names in the drug label.

Look-Alike Drug Names

There is limited information regarding Pirfenidone Look-Alike Drug Names in the drug label.

Drug Shortage Status

Price

References

The contents of this FDA label are provided by the National Library of Medicine.